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Abstract: Dementia is a neurodegenerative disorder characterized by 
progressive and continuous loss of cognitive functions. The neuropsychiatric 
symptoms include apathy; agitation and depression. As the disorder progresses, 
the patient gradually becomes dependent on others to perform routine daily 
activities. Various underlying diseases or disorders are the root cause of the 
syndrome of dementia. Each of these disorder or disease is characterized by 
a specific signs and symptoms in combination with a presumed underlying 
neuropathology. Alzheimer’s disease is the most prevalent cause of dementia. 
The second most prevalent cause is vascular dementia. In this review, the 
clinical types, pathophysiology and pharmacotherapy is summarized.
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1. iNtrODUCtiON
Learning and memory are two fundamental cognitive functions that confer us the ability to accumulate knowledge from our experiences (Liu et al., 2009). Learning refers to acquisition of any new information about the 
event in particular surroundings and subsequent retrieval of this information is 
referred to as memory (Okano et al., 2000). Memory, one of the most complex 
functions of the brain, comprises of multiple components such as perception/
sensation, registration, consolidation, storage, retrieval and decay/forgetting 
(Lindebooma and Weinstein, 2004; Parle et al., 2006). Memory may be sensory 
(registration), short-term memory and long-term memory (Nader, 2000). 
Consolidation refers to the process of conversion of short-term memory to long-
term memory (Robbins and Murphy, 2006). Sensory memory (registration) is 
defined as a process of sensory perception and an ability to retain the perceived 
sensory signals in the sensory areas of the brain for relative short interval of 
time, following actual sensory experience. The incoming information first 




a few seconds or less. For instance, look at a flower and then close your eyes. 
An icon, of fleeting mental image of the flower will persist for about one-half 
second (Iconic memory). Similarly, information you hear is held in sensory 
memory as an echo (Echonic memory) for up to 2 seconds (Schweickert, 
1993; Nader, 2000). In general, sensory memory holds information just long 
enough so that some of it can be transferred to the second memory system. 
Short-term memory (STM) holds small amounts of information for relatively 
brief periods; it is also called as working memory. It operates through central 
executive, visuo-spatial sketchpad and phonological loop. A central executive 
coordinates the material to focuss on reasoning and decision-making. The visuo-
spatial sketchpad concentrates on visual and spatial information, while the 
phonological loop is responsible for holding and manipulating material related 
to speech, work and numbers (Ellis and Nathan, 2001). STM can be prolonged 
by rehearsal, the more time STM is rehearsed, the greater its chances of being 
stored in LTM. Long-term memory has the capacity to hold the information 
for months to years, it may be classified into declarative (explicit) and non-
declarative (implicit) memory (Budsen and Price, 2005).
Declarative memory is a deliberate process to remember factual information 
such as names, faces and dates. It is stored in medial temporal lobe (mainly 
hippocampus) and diencephalons (Shaprine & Eichenbaum 2000; Budsen and 
Price, 2005). Non-declarative memory is unintentional recollection of earlier 
experiences (Nelson et al., 1992). It operates spontaneously without conscious 
efforts and it is stored in striatum, neocortex, amygdala and cerebellum. The 
CA1 (Deadwyler and Hampson, 1999) and CA3 neurons (Deadwyler and 
Hampson, 1999; Ramirez-Amaya et al., 1999) of hippocampus are responsible 
for spatial learning and memory (Gilbert, 2000). Declarative memory is 
divided into semantic memory and episodic memory. Semantic memory deals 
with general knowledge and facts about the world e.g. mathematical figures 
and historical dates (Budsen and Price, 2005) and episodic memory refers to 
biographical details of an individual such as accident and memorable events 
(Budsen and Price, 2005). Procedural memory is a form of non-declarative 
memory and it refers to skills and habits such as riding a bicycle (Budsen and 
Price, 2005). Priming and perceptual learning, simple classical conditioning 
and non-associative learning are other forms of non-declarative memory 
(Budsen and Price, 2005).
2 AMNesiA Vs DeMeNtiA
Amnesia is a condition in which memory is disturbed. Often this condition is 
reversible e.g. alcohol/wine-induced amnesia. Amnesia may develop either a an 




infarcts, head trauma and Alzheimer’s disease or consumption of alcohol (Fama 
et al., 2004; McIntosh and Chick, 2004), chronic drug abuse (Vik et al., 2004) 
and certain chemical agents utilization (Chun, 2005). The memory impairment 
in amnesia is usually global, being both anterograde and retrograde (Cipolotti 
et al., 2001). Anterograde amnesia, is an inability to form new memories (Park 
et al., 2007), where as retrograde amnesia, is failure to retrieve old memories 
(Anand et al., 2007). Damage to the hippocampus, fornix, mamillary bodies, 
anterior and medial thalamic nuclei or basal forebrain can result in anterograde 
amnesia. Some authors have reported that severe anterograde amnesia is 
caused by bilateral lesions in medial temporal lobe structures (Di Gennaro et 
al., 2006), anteromedian thalamus (Carrera et al., 2004) or fornix (Poreh et al., 
2006). Cases of anterograde amnesia were also developed by a unilateral lesion 
in mamillary body (Kupers et al., 2004), anterior medial thalamus (Summers, 
2002), or hippocampus (Park et al., 2007). 
Dementia refers to a syndrome that is characterized by progressive 
deterioration of cognitive functions. The neuropsychiatric symptoms include 
apathy; agitation and depression. As the disorder progresses, the patient 
gradually becomes dependent on others to perform routine daily activities. 
Various underlying diseases or disorders are the root cause of the syndrome of 
dementia. Each of these disorder or disease is characterized by a specific signs 
and symptoms in combination with a presumed underlying neuropathology. 
Alzheimer’s disease is the most prevalent cause of dementia. The second most 
prevalent cause is vascular dementia (Chen et al., 2009). It is often difficult 
to distinguish between subtypes of dementia. However, most dementias are 
progressive, irreversible and incurable. The risk factors and protective factors 
associated with dementia are listed in Table 1. The main risk factor for dementia 
is age. Prevalence is 2 % in those aged 65-69 years compared with 20% in 
those aged 85-89. The terms senile and pre-senile dementia have been used to 
differentiate between patients under or over 65 years but these are no longer in 
common use because the two types share some etiological features. Dementia 
is estimated to affect 24.3 million people worldwide. There are 4.6 million new 
cases of dementia every year and it is suggested that this figure will double every 
20 years, reaching over 80 million by 2040 (Husband and Worsely, 2006). 
3 CliNiCAl tYPes AND PAtHOPHYsiOlOGY OF DeMeNtiAs
Dementia, according to the Diagnostic and Statistical Manual of Mental 
Disorders IV (DSM-IV), is a syndrome that may be caused or characterized 
by multiple cognitive deficits, which include memory impairment and at least 
one of the following: aphasia, apraxia, agnosia or disturbance in executive 




dementia should not be made during the course of a delirium. (A dementia and 
a delirium may both be diagnosed if the dementia is present at times when the 
delirium is not present.)
Dementia may occur due to both anatomical and biochemical changes in 
the brain. The behavioral and psychological symptoms of dementia include 
agitation/irritability/mood labiality, anxiety, apathy, delusion, depression 
symptoms, disinhibition, euphoria, hallucinations, loss of appetite and sleep 
disturbances (Tampi et al; 2011). Dementia has been etiologically associated 
with numerous heterogeneous conditions listed in Table 2 and is categorized in 
few subtypes according to its causes.
table 1: Risk factors and protective factors of dementia
Risk factors Protective factors 
Age ++ Apolipoprotein ε2 allele ++
Women + Low cholesterol level +/-
Low education + Statins +/-
First degree relative + Antihypertensive drug treatment +
Down’s syndrome + Moderate alcohol consumtion +/-
Head trauma + Hormone replacement therapy (estrogen) +/-
Apolipoprotein ε4 allele ++ Aspirin -
Aluminum level +/- Nonsteroidal anti-inflammatory drugs +/-
Hypertension + Dietary factors (vitamin E, antioxidants) +/-
Depression +
Lifestyle (active life, leisure 
activities, social support and 
network)
+/-
Mild cognitive impairment ++




consumption (3 drinks/day) +
Hyperlipidemia +
Hyperhomocysteinemia, low 
serum folate levels +
Previous mental decline +/-
Note: ++=confirmed; +=notable; +/-=controversial; -=negative. Adapted from 
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 Acquired hepatocerebral degeneration
 Endocrinopathies
 Thyroid, parathyroid disturbances
 Cushing’s syndrome

























 Lead, mercury, arsenic
 Nickel, aluminum










Cortical dementia: dementias in which predominant involvement of •	
dysfunction is in cortex region
Subcortical dementia: dementias having predominant involvement of •	
the white and grey matter structures such as basal ganglia, thalamus and 
frontal lobe projections.




Alzheimer’s disease (AD) accounts for around 60 per cent of all cases of dementia 
(Fratiglioni et al., 2007). AD is a progressive neurodegenerative condition that 
may be of presenile or senile onset depending on whether the occurrence of 
disease is before or after the age of 65 years. Clinically, the patient presents 
itself as a progressive dementia of insidious onset with subtle personality 
alterations eventually resulting in complete anomia, agnosia and apraxia. The 
disease is occasionally accompanied by steep disturbance, anxiety, aggression 
and agitation (Cummings, 2004). Histopathological evidence of senile plaques 
and neurofibrillary tangels, either at autopsy or under rare circumstances, when 
biopsy is obtained, constitutes the most reliable diagnosis. Senile plaques are 
the clusters of degenerative nerve endings containing extracellular deposits 
of β-amyloid. Neurofibrillary tangles are microscopic paired helical filaments 
mainly made up of phosphorylated tau proteins (Kamphuis and Wurtman, 
2009). Neocortex and hippocampus are the major regions characterized by 
these abnormalities. In fact, severity of cognitive impairment in AD correlates 
with the density of these plaques in neocortex. Biochemically, AD affects 
some of the selective neurotransmitters and neuromodulators. There has been 
a considerable deficiency of acetylcholine in brain of virtually all the patients 
of AD, who have been studied (Shah et al., 2008). The serotonergic and 
noradrenergic systems also seem to be affected particularly when the onset of the 
disease is before the age of 75 years. Putative pathogenic mechanisms include 
glutamate neurotoxicity, free radical production, aluminum accumulation, 
apoptosis and inflammation (Silvestrelli et al., 2006).
3.1.2. Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) accounts for 15 to 20 per cent of dementia 
cases. The disease seems to lie somewhere between AD and Parkinson’s 
disease. DLB has distinct microscopic features: patients present with Lewy 




Neurofibrillary tangles are less commonly seen. Lewy bodies are eosinophilic 
cytoplasmic inclusions that are distinct from neurofibrillary tangles. They 
contain a protein called alpha-synuclein, which is normally responsible for 
synaptic plasticity. Alpha- synuclein also appears to regulate the size of 
presynaptic vesicular pools of neurotransmitters and, therefore, influences 
neurotransmission. In DLB, heavily phosphorylated alpha-synuclein becomes 
cross linked to form the insoluble complexes that are Lewy bodies. Lewy bodies 
also contain a variety of inflammatory markers (eg. interleukins), proteases, 
BA and lipids. Lewy body development is accompanied by neuronal loss with 
specific deficits in cholinergic and dopaminergic neurotransmission (Husband 
and Worsley 2006). 
3.1.2. Fronto-temporal dementia
FTD, sometimes also referred to as fronto-temporal lobar degeneration 
(FTLD), is the second commonest cause of dementia in younger people (< 
65 years) (Ratnavalli, 2002), and produces focal atrophy of the frontal and/
or anterior temporal lobes, with concomitant cognitive features (Neary et al., 
2005). Two major presentations are recognized: 
(i) A behavioural variant (bvFTD)- bvFTD is characterised by a prominent 
change in personality and social behaviour, with apathy and/or disinhibition, 
emotional blunting, stereotyped or ritualised behaviours, loss of empathy 
alterations in appetite and food preference with limited or no insight. These 
changes reflect involvement of orbital and mesial frontal lobes (Sjogren 
and Andersen, 2006). 
(ii) A language variant, which in turn is divided in two different patterns: 
semantic dementia (SD) and progressive non-fluent aphasia (PNFA). 
In SD, there is a profound loss in conceptual knowledge (or semantic 
memory) causing anomia and impaired comprehension of words, objects, 
or faces. In PNFA, by contrast, there is a gradual loss of expressive 
language abilities with impairments in phonological (sound-based) and 
grammatical aspects of language production. Repetition of multisyllabic 
words and phrases is impaired but, in contrast to SD, word comprehension 
and object recognition are well preserved (Lillo and Hodges, 2009). 
3.2 subcortical dementias
3.2.1 Parkinson’s disease
The one-third patients with Parkinson’s disease are prone to subcortical and 
progressive dementia. The neurodegeneration is not only confined to substantia 




cerebral cortex. Furthermore, the underlying neurochemical deficits associated 
may be losses of cholinergic, dopaminergic and noradrenergic innervations 
(Kulisevsky and Pagonabarraga, 2009; Hindle, 2010).
3.2.2 Huntington’s disease
Huntington’s disease (HD) is an autosomal dominant disorder with an average 
course of 15 to 20 years. It typically affects patients between 30 and 50 years 
of age and has a prevalence of between four and seven per 100,000 worldwide 
(Roze et al., 2010). The main and initial symptom of HD is “fidgety” 
movements (chorea) but cognitive decline, attention deficit and depression 
follow. Development of bipolar disease and schizophrenia is common in patients 
with HD. The gene mutation responsible has been identified as a polymorphic 
trinucleotide repeat in chromosome 4p. This is responsible for producing mutant 
forms of the Huntington protein. This is normally found in cell cytoplasm but, 
in HD, it is seen in nuclei. The mechanism of neurodegeneration as a result of 
this genetic mutation is unclear and the net result is a deficit in GABAeric and 
increased dopaminergic activity (Krobitsch and Kazantsev, 2011).
3.2.3. Wilson’s disease
The characteristic extrapyramidal signs are seen in the patients with Wilson’s 
disease. The symptoms of depression, disinhibition, personality changes and 
reduced impulse control are common; however the cognitive deficits are usually 
mild. The psychopathological features observed here are by virtue of abnormal 
and destructive deposition of copper in the basal nuclei; due to an inherited 
defect in the copper-carrying serum protein ceruloplasmin (Shimizu, 2004).
3.2.4. Normal pressure hydrocephalus
The characteristic triad of clinical symptoms of this neuropsychiaric syndrome 
includes motoric and psychopathological features i.e. an early abnormal 
gait (resembling the steps of spastic paraparesis); subcortical dementia with 
particularly severe apathetic features and urinary incontinence (that may not 
appear until late in the course. The cognitive difficulties appear with the onset 
of the incident. The neuropsychiatric deficits are due to the tissue destruction 
by stretching as a result the chronic hydrocephalus (Kazui, 2008).
3.3 Mixed dementias and dementia in disseminated brain diseases
3.3.1 Vascular dementia
Vascular dementia (VaD) remains the second most common form of dementia 




of brain injury produced by cerebrovascular disease, either hemorrhagic or 
ischemic, or by hypoperfusive lesions resulting from cardiac disease or 
circulatory failure (Roman, 2005). The high prevalence of VaD in the aging 
population is a reflection of the fact that stroke and ischemic heart disease 
(IHD) are the two leading causes of morbidity and mortality in the elderly. The 
small brain infarcts leads to cognitive deterioration when they have enough 
cumulative effects on critical areas of the brain, results VaD. Depending 
upon the nature, extent and site of neuropathological lesion, the VaD may be 
categorized into several subtypes such as-
(i) Large vessel vascular dementia
(a) Multi-infarct dementia:- Multiple large complete infarcts localized in 
cortico–subcortical area, mainly in white mater, are responsible for 
dementia. 
(b) Strategic infarct dementia:- Single brain infarct, often lacunar in size, 
damages functionally critical areas of the brain (e.g. angular gyrus, 
thalamus, basal forebrain, posterior cerebral artery, and anterior 
cerebral artery territories). 
(ii) Small-vessel vascular dementia:-
(a) Subcortical: It is involved in Binswanger disease, CADASIL (Cerebral 
Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy), and characterized by multiple lacunes with 
extensive perifocal incomplete infarctions.
(b) Cortical and subcortical: It is involved in hypertensive, arteriolosclerotic 
angiopathy, amyloid angiopathies and collagen-vascular disease. 
(iii) Hypoperfusive vascular dementia:-
 Ischemic-hypoxic dementia is a characteristic of diffuse anoxic-ischemic 
encephalopathy, and characterized by restricted injury due to selective 
vulnerability i.e. mesial temporal lobe sclerosis, incomplete white-matter 
infarction and border-zone infarction.
(iv) Hemorrhagic vascular dementia:
 Hemorrhagic dementia, occur mainly in traumatic subdural hematoma, 
subarachnoid hemorrhage, cerebral hematoma and venous thrombosis.
3.3.2 Infection associated dementia
HIV dementia: HIV dementia (HIVD) is likely to become more common, 
considering the rise in HIV infection. It is estimated that up to 30 percent 
of patients with HIV will develop HIVD. HIVD is a subcortical dementia 




apathy and emotional lability. The pathological mechanism involved in HIVD 
appears to be apoptosis in neuronal cells as a result of various neurotoxic 
chemicals (proteases, cytokines etc) shed from infected macrophages and glial 
cells within the CNS. There is some evidence to suggest that treatment with 
antiretroviral agents could reduce the incidence of HIVD and, in patients who 
have developed the dementia, possibly stop or slow progression (Sharma and 
Bhattacharya, 2009).
Creutzfeldt-Jakob Disease: It is a dementia with an extremely rapid course, 
caused by transmissible infectious agent, the prion. Cognitive deterioration is 
progressive, widespread and accompanied by pyramidal and extrapyramidal 
signs i.e myoclonic jerks, ataxia and muscle rigidity. Death generally occurs 
in 6-12 months. The pathological changes are widespread in the cortex and 
the subcortical structures. Spongiform change in neurons is characteristic and 
neuronal loss and astrocytic proliferation occur (Dupiereux et al., 2009).
Neurosyphilis: It may evolve into different types of dementia if left untreated. 
The most severe form is general paresis, often evident 15-20 years after the 
original infection. The dementia may be easily recognized in the advanced 
state by characteristic signs, such as pupillary abnormalities, dysarthria, tremor 
of the tongue and hypotonia (Nagano and Abe, 2004).
Chronic meningitis caused by chronic bacterial or fungal infections, 
can eventually cause progressive dementia, with fluctuations in arousal and 
cognitive performance, apathy, lethargy, disorientation and cranial nerve 
abnormalities (Herta et al., 2005).
Herpes simplex encephalitis may cause major neurological and cognitive 
sequelae (Cyngiser, 2008). 
3.3.3 Metabolic and toxic dementias
Metabolic and toxic dementias form a heterogenous group of diseases of 
special interest to the psychiatrist because they are potentially reversible 
and relatively frequent in medical settings (Craft, 2009). Dementia in these 
conditions has predominantly subcortical features but may have mixed 
characteristics. Progression of dementia is usually dependent on the chronicity 
of the metabolic or toxic condition, and the further course tends to be disease-
specific. Hippocampal neurons are probably most vulnerable to anoxic injury 
but are also vulnerable to severe hypercholesterolemia and to repeated or severe 
episodes of hypoglycemia (Yaffe et al., 2004). Hypothyroidism can produce 
subcortical damage through a mechanism of relative cerebral hypoxia. Vitamin 
B
12




cortical white matter, the optic tracts and the cerebeller peduncles (Osimani et 
al., 2005). In pellagra, nicotinic acid and probably other vitamin B deficiencies 
may lead to neuronal destruction (Hillborn and Marttila, 2010). Alcoholic 
dementia is one possible complication of chronic alcoholism (Hulse et al., 
2005). This situation may be a result of associated malnutrition, especially of 
B vitamins and particularly thiamine. Thiamine (vitamin B
1
) deficiency causes 
Wernicke’s encephalopathy. Prolonged untreated thiamine deficiency can result 
in an irreversible dementia/amnestic syndrome (Korsakoff’s psychosis) (Phaf 
et al., 2000). Dementing syndromes may also occur in chronic intoxication 
with medications (prescribed or abused by patients). The onset is accidental, 
and physicians should be alert to the possibility of this reversible dementia. 
Elderly patients are more vulnerable to developing the dementing syndrome 
(Bassil & Morley, 2010).
3.3.4 Neoplastic-associated dementia: 
Neoplastic diseases (depending upon tumor location, extent as well as rapidity of 
tumor growth) essentially may produce any kind of neuropsychiatric symptoms. 
Meningioma tumor present in frontal lobe is associated with symptoms like 
cognitive loss with apathy, negativism and akinesia. Limbic encephalopathy is 
a complication of small cell lung carcinoma and may manifest with dramatic, 
sudden onset of memory loss. A full dementia syndrome may eventually 
develop (Staropoli, 2008).
3.3.5 Dementia following traumatic brain injury: 
Traumatic brain injury may cause variety of cognitive difficulties. The severe 
trauma with loss of consciousness is called as post-traumatic amnesia. 
Dementia pugilistica called as dementia of boxers, commonly starts with signs 
of ataxia, dysarthria and Parkinson’s like extrapyramidal signs before cognitive 
effects are appreciated (Dekosky et al., 2010).
3.3.6 Psychiatric disorders associated dementia: 
The relationship between dementia and depression is complex. Pseudodementia 
is a term used to describe the condition of depressed patients who perform 
poorly on cognitive tasks because of lack of interest and motivation. However, 
dementia syndrome of depression (DSD) occurs during episodes of severe 
mood disorders (Korczyn and Halperin, 2009). 
A wide variety of medications have been proposed to treat different types 
of dementia. Table 3 enlists the common pharmacotherapeutic options to 





table 3: Pharmacotherapy of Dementia
Drug Mode of action evaluation/Comments reference 
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ACh
Not effective alone/high 
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isolated cognitive measures. 


























Memantine NMDA-receptor partial antagonist
Safe; may be useful in AD, 
VaD and mixed dementia. 










Modest clinical effect, 
possibly due to mood 
elevation.
Olin et al., 
2001
Estrogen
Increase blood flow 
to brain, affect nerve 
growth factor, Prevent 
atrophy of cholinergic 
neuron, reduce 
oxidative stress
Some clinical trials have 
shown improvement in 
cognition function
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in rheumatoid groups vs. 
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Based on animal studies, 
NIA workgroup concluded 






influx that occurs with 
cellular changes, may 
slow progression of 
disease
Less deterioration on some 






inhibitor, acts as 
asn antioxidant and 
increases adrenergic 
stimulation
Improvements in sone 
cognitive testing, was 
comparable to vitamin 
E in delaying disease 
progression.
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